Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results [Canadian Business Journal (Canada)]
Eupraxia Pharmaceuticals Inc. (EPRX)
Company Research
Source: Canadian Business Journal
Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GIEnrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026Completed $80.5 million public offering supported by leading life science investorsCash runway to fund pipeline development and operations into the first half of 2028VICTORIA, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, today announced its financial results for the third quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.“The compelling 52-week data from our RESOLVE trial reported this quarter further reinforce the potential of EP-104GI as a highly effective and
Show less
Read more
Impact Snapshot
Event Time:
EPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EPRX alerts
High impacting Eupraxia Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
EPRX
News
- Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here's Why [Yahoo! Finance]Yahoo! Finance
- Eupraxia Pharmaceuticals (NASDAQ:EPRX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=EPRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">WalMarketBeat
- Individual investors account for 43% of Eupraxia Pharmaceuticals Inc.'s (TSE:EPRX) ownership, while institutions account for 26% [Yahoo! Finance]Yahoo! Finance
- Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=EPRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
- Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial ResultsGlobeNewswire
EPRX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/13/25 - Form SCHEDULE
- EPRX's page on the SEC website